News Article | April 17, 2017
Oracle SPARC systems are engineered from the cloud and provide customers with effortless security, breakthrough efficiency, and straightforward simplicity. “Cloud is the way to go and we try to deliver that in the form of a platform that you can rely upon, that can scale, scale massively, scale reliably. The thing about SPARC in contract to other chips is the software that runs on it is highly reliable. You can heat it, you can beat it, you can give it a lot of load, but it doesn’t break, it just keeps running.”
News Article | April 17, 2017
Hear Masood Heydari, SVP of SPARC Engineering, discuss details of Oracle's servers designed for cloud and scale-out, which provide security by default, better core efficiency for cloud apps, and accelerate data analytics at X86 commodity cost points
News Article | December 23, 2016
A consortium directed by UCLA's Dr. Kalyanam Shivkumar has received a three-year, $8.6 million grant from the National Institutes of Health to map the heart's nervous system. The group's goal: To conduct research that leads to new ways to treat cardiovascular disease by targeting nerves in the heart's nervous system. More than 800,000 people in the U.S. die each year from cardiovascular diseases such as heart failure, arrhythmia and hypertension. These problems often are linked to the autonomic nervous system, the part of the nervous system that signals the heart to beat and controls breathing, digestion and other body processes that typically happen without conscious effort. Researchers believe that modulating those electrical signals holds promise as a way to treat heart failure and other common cardiovascular problems. "Understanding the nervous system's control of the heart is such a complex problem that it requires a collaborative approach, and we're pleased that so many experts are coming together for this initiative," said Shivkumar, the study's lead investigator and director of the UCLA Cardiac Arrhythmia Center and Electrophysiology Programs. "Our goal is to precisely map the heart's anatomy and code the function of the nerves that control the heart from a very basic level all the way to clinical studies in humans." UCLA is one of seven institutions participating in the project. Principal investigators at the other universities are Dr. Viviana Gradinaru of Caltech, Dr. Stephen Liberles of Harvard University, Dr. Charless Fowlkes of UC Irvine, Dr. Irving Zucker of the University of Nebraska Medical Center, Dr. Beth Habecker of Oregon Health and Science University and Dr. David Paterson of Oxford University. The information the consortium produces could point the way to new therapies that target neural structures, and it could suggest ways for scientists to create more effective electrical stimulation therapies based on the methods being used today, said Shivkumar, who is also chief of the UCLA Cardiovascular Interventional programs and a professor of medicine, radiology and bioengineering at the David Geffen School of Medicine at UCLA. "Understanding how the nervous system controls the heart offers researchers a tremendous opportunity to open up new paths to treat cardiac disease," said Dr. Kelsey Martin, dean of the David Geffen School of Medicine. "We are thrilled that our UCLA team is leading the charge on this exciting new research." The award is from an NIH program called Stimulating Peripheral Activity to Relieve Conditions, or SPARC, which supports research on how the electrical signals of the peripheral nerves that connect the brain and spinal cord to the rest of the body control internal organ function. The UCLA-led consortium is one of 27 multidisciplinary research teams that received SPARC awards in 2016; the grants totaled more than $20 million.
News Article | December 15, 2016
Considerable evidence has indicated that the drug metformin, used for more than 50 years to treat type 2 diabetes, also can prevent or slow the growth of certain cancers; but the mechanism behind its anticancer effects has been unknown. Now a team of Massachusetts General Hospital (MGH) investigators has identified a pathway that appears to underlie metformin's ability both to block the growth of human cancer cells and to extend the lifespan of the C.elegans roundworm, implying that this single genetic pathway plays an important role in a wide range of organisms. "We found that metformin reduces the traffic of molecules into and out of the nucleus - the 'information center' of the cell," says Alexander Soukas, MD, PhD, of the MGH Center for Human Genetic Research, senior author of the study in the Dec. 15 issue of Cell. "Reduced nuclear traffic translates into the ability of the drug to block cancer growth and, remarkably, is also responsible for metformin's ability to extend lifespan. By shedding new light on metformin's health-promoting effects, these results offer new potential ways that we can think about treating cancer and increasing healthy aging." Metformin's ability to lower blood glucose in patients with type 2 diabetes appears to result from the drug's effects on the liver -- reducing the organ's ability to produce glucose for release into the bloodstream. Evidence has supported the belief that this is the result of metformin's ability to block the activity of mitochondria, structures that serve as the powerhouse of the cell. But while that explanation appears to be fairly straightforward, Soukas explains, more recent information suggests the mechanism is more complex. Several studies have suggested that individuals taking metformin have a reduced risk of developing certain cancers and of dying from cancers that do develop. Current clinical trials are testing the impact of metformin on cancers of the breast, prostate and pancreas; and several research groups are working to identify its molecular targets. Soukas's team had observed that, just as it blocks the growth of cancer cells, metformin slows growth in C.elegans, suggesting that the roundworm could serve as a model for investigating the drug's effects on cancer. Their experiments found that metformin's action against cancer relies on two elements of a single genetic pathway - the nuclear pore complex, which allows the passage of molecules into and out of the nucleus, and an enzyme called ACAD10. Basically, metformin's suppression of mitochondrial activity reduces cellular energy, restricting the traffic of molecules through the nuclear pore. This shuts off an important cellular growth molecule called mTORC1, resulting in activation of ACAD10, which both slows the growth and extends the lifespan of C.elegans. In human melanoma and pancreatic cancer cells, the investigators confirmed that application of drugs in the metformin family induced ACAD10 expression, an effect that depended on the function of the nuclear pore complex. Without the complete signaling pathway - from mitochondrial suppression, through nuclear pore restriction to ACAD10 expression - cancer cells were no longer sensitive to the effects of metformin-like drugs. "Amazingly, this pathway operates identically, whether in the worm or in human cancer cells," says Soukas, who is an assistant professor of Medicine at Harvard Medical School. "Our experiments showed two very important things: if we force the nuclear pore to remain open or if we permanently shut down ACAD10, metformin can no longer block the growth of cancer cells. That suggests that the nuclear pore and ACAD10 may be manipulated in specific circumstances to prevent or even treat certain cancers." The essential contribution of ACAD10 to metformin's anticancer action is intriguing, Soukas adds, because the only published study on ACAD10 function tied a variant in the gene to the increased risk of type 2 diabetes in Pima Indians, suggesting that ACAD10 also has a role in the drug's antidiabetes action. "What ACAD10 does is a great mystery that we are greatly interested in solving," he says. "Determining exactly how ACAD10 slows cell growth will provide additional insights into novel therapeutic targets for cancer and possibly ways to manipulate the pathway to promote healthy aging." Lianfeng Wu, PhD, of the MGH Center for Human Genetic Research (CHGR) is lead author of the Cell paper. Additional co-authors are Ben Zhou, PhD, Christopher Webster, PhD, Michael Kacergis, MS, and Michael Talkowski, PhD, MGH CHGR; Noriko Oshiro-Rapley, PhD, Fan Mou, PhD, and Christopher Carr, PhD, MGH Department of Molecular Biology; Man Li, PhD and Bin Zheng, PhD, MGH Cutaneous Biology Research Center; and Joao Paulo, PhD and Steven Gygi, PhD, Harvard Medical School. Support for this study includes NIH grants R03DK098436, K08DK087941, R01DK072041, and R01CA166717, a Broad Institute SPARC Grant, and the Ellison Medical Foundation New Scholar in Aging Award. Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."
News Article | December 19, 2016
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) today provided an update on the timeline for the INTERCEPT Blood System for Red Blood Cells (RBCs) in Europe. The target timing for CE Mark submission has been extended, and the company’s European red cell study in chronic anemia patients has completed enrollment. Due to the need for additional time to complete quality control tests on the Chemistry, Manufacturing, and Control (CMC) registration lots required for regulatory submission, the company now plans to provide an update on new submission timing on its 4Q16 earnings call in early March. The CE Mark process for the INTERCEPT Blood System for Red Blood Cells includes review and approval by both TŰV SŰD as the Notified Body and Irish Health Products Regulatory Authority (HPRA) as the Competent Authority. Accordingly, a new submission filing date will need to be scheduled with TŰV SŰD Product Service GmbH. Cerus’ SPARC trial (A Randomized Controlled Study to Evaluate Efficacy and Safety of INTERCEPT Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion) has now reached its enrollment target of at least 70 evaluable patients, and the company expects that study data will be available in time to support its anticipated European product launch. The SPARC study is being conducted in transfusion-dependent thalassemia major patients, an inherited blood disorder of abnormal hemoglobin resulting in excessive destruction of red blood cells. “Chronic anemia patients such as those with thalassemia major and sickle cell disease require more blood transfusions than almost any other patient group, putting them at elevated lifetime risk for exposure to existing and emerging pathogens,” said Richard Benjamin, Cerus' chief medical officer. “Our ability to provide safety and efficacy data generated by the chronic anemia study at the time of our anticipated product launch will be an important supplement to the clinical data already included for submission.” The SPARC study is a randomized, crossover trial in which patients receive two periods of transfusion support, consisting of one period each of conventional and INTERCEPT-treated RBCs over approximately 6 - 9 months in total. The primary efficacy endpoint is hemoglobin usage and the primary safety endpoint is immunogenicity. Hemoglobin usage was selected as the primary efficacy endpoint because it is correlated with the ability of transfused red blood cells to oxygenate tissues, persist in circulation, and suppress endogenous erythropoiesis. This endpoint is clinically relevant because hemoglobin consumption is correlated with iron burden, an important complication for patients despite availability of chelation therapies. Red blood cells are disc-shaped cells containing hemoglobin which deliver oxygen from the lungs to all body tissues. Red blood cells are the most frequently transfused blood component, with over 80 million units transfused globally each year. Patients typically receive red blood cell transfusions to offset blood loss after trauma and during surgery, or to increase hemoglobin levels in patients with hereditary anemia. ABOUT THE INTERCEPT BLOOD SYSTEM FOR RED BLOOD CELLS Cerus reported positive results of the INTERCEPT Blood System for Red Blood Cells from a European Phase III acute clinical trial in 2015. If approved, the INTERCEPT Blood System for RBCs will be the only system commercially available in Europe to enhance the safety of red blood cell transfusions through pathogen inactivation. In addition to plans to submit for CE Mark registration in Europe, Cerus is also currently in dialogue with the U.S. Food & Drug Administration regarding a protocol design for a Phase III pivotal red blood cell study to be conducted in the continental United States. Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus. INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation. Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements concerning Cerus’ plans to pursue CE Mark approval in Europe for the red blood cell system and the timing thereof; the potential for CE Mark approval for and commercial launch of Cerus’ red blood cell product in Europe; and Cerus’ plans to present data regarding the study results from its study in transfusion-dependent thalassemia major patients. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the uncertain and time-consuming regulatory process, including completion of all of the CMC activities necessary to support a regulatory submission; that Cerus may be unable to file for CE Mark approval of the red blood cell system in Europe in the anticipated timeframe or at all, and even if filed, that Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell system in a timely manner or at all; Cerus’ belief that the results from its clinical trial will support its CE Mark submission, Cerus’ development of the INTERCEPT Blood System for red blood cells and its therapeutic potential, the risks associated with the uncertainty of clinical trial results, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including in Cerus‘ Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 4, 2016. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
News Article | December 6, 2016
Since 1990, MDSi's focus has been on reducing our customers' costs and minimizing their risk across the entire Infrastructure Lifecycle. As one of the keystones of this initiative, MDSi focuses on reducing customer CAPEX by providing readily available and fully supported, lowest-cost hardware solutions from multiple OEMs. Today, MDSi is proud to announce the extension of our product offerings to include fully supported Oracle SPARC and Pure Storage hardware. “The addition of Oracle SPARC and Pure Storage is a natural fit alongside MDSi’s current hardware offerings. Partnering with two industry leading technologies give us the ability to meet our customer’s needs for both on premise and future cloud infrastructure” says Dale Howerton, Product Manager Server and Storage. “With the exponential growth of Big Data there naturally becomes an ever increasing need to accurately and efficiently analyze and process said data. In the ongoing support of our customer’s needs, we believe the addition of Oracle and Pure to our existing Cisco UCS offerings, positions MDSi as the premier hardware and service supplier as we take on Big Data, Analytics, and Cloud Solutions.” As companies continue to migrate and partition their infrastructures to the cloud, security is of utmost importance without sacrificing performance. Contact MDSi to learn more about the hardware and service solutions we offer that will not only protect and perform, but will minimize your total cost of ownership. About MDSi Headquartered in Alpharetta, Georgia, MDSi provides tailored technology solutions for telecom, cable, and data center infrastructure environments— focused on reducing costs, centralizing visibility, and optimizing value at every stage of the asset lifecycle. MDSi programs couple asset purchase and deployment requirements with asset lifecycle management to achieve ongoing cost avoidance, simultaneously streamlining technology deployments and operations. For more information visit http://www.mdsiinc.com. About Oracle Oracle was the first software in Silicone technology for: security, performance, and efficiency. With more than 400,000 customers across 145 countries, Oracle has made a name in the technology field. Oracle’s enterprise servers deliver advanced security, high performance, simplified management, and high availability with a lower cost of ownership. While the business continues to demand new applications in shorter timeframes, it has become increasingly difficult to maintain control of your existing UNIX enterprise infrastructure without compromising performance, manageability and security. In addition, implementing an enterprise cloud strategy has become paramount to being able to better reach and engage with customers. Oracle SPARC Servers deliver breakthrough performance, manageability, and security, making them the most modern Unix platforms on the market. Oracle SPARC server solutions are “cloud ready”, offering the flexibility to leverage all the benefits of cloud at your pace, whether its today or in the future. Only Oracle delivers an enterprise grade infrastructure that integrates both on-premises SPARC servers and public cloud, enabling you to seamlessly extend existing UNIX application infrastructure investments to the cloud without modification, accelerating time to value for your business at a reduced cost. About Pure Storage Pure Storage has been a leader in the flash storage market since 2007. Pure Storage accelerates possible, transforming businesses in ways previously unimagined. The company’s disruptive software-driven, all-flash storage technology combined with a customer-friendly business model drives business and IT transformation for customers through dramatic increases in performance and efficiency at lower costs. With Pure's industry leading Net Promoter Score, Pure customers are some of the happiest in the world, and include large and mid-size organizations across a range of industries. With Pure Storage, companies push the boundaries of what's possible to become faster, smarter and more innovative. Headquartered in Mountain View, CA, Pure Storage has locations across the United States to be readily and easily available to all their customers. For three years in a row, Pure Storage has been named a leader in Flash Storage via the Gartner Magic Quadrant for Solid-State Array. MDSi is excited to work with the Pure Team in progressing their vision.
News Article | December 7, 2016
Global Service robotics market is expected to reach $34.7 billion by 2022, with a CAGR of 23.9% from 2015 to 2022, according to a new report by published by Allied Market Research. Portland, OR, December 07, 2016 --( Increasing need for safety along with government regulations for labor protection drives organizations to adopt service robotics for enhanced safety at workplace. The growing penetration of mobile devices facilitates the development of advanced robotic systems and boosts the growth of market. Vendors in the market focus on developing affordable and energy-efficient robots for small and medium enterprises to cater to the growing requirements of consumers. The significant rise in investments in R&D for the development of service robots along with the establishment of organizations including Standardized Procedures for the Advancement of Robotic Combat (SPARC) and International Federation of Robotics (IFR), further fosters the growth of the market. View more details of the report at: https://www.alliedmarketresearch.com/service-robotics-market Europe dominated the global service robotics market in 2014 in terms of revenue and is expected to maintain its dominance during the forecast period owing to the high demand of service robots from domestic, healthcare, and defense sectors. However, LAMEA is expected to exhibit highest growth in revenue, at a CAGR of 26.6% during the forecast period. Professional service robots are used in healthcare; defense, rescue, and security; field; logistics; and construction industries. The segment of professional service robotics generated $3.9 billion in 2014 owing to high demand of automation from these sectors. Reduction in labor costs, increased operational efficiency, and delivery of high-quality services with improved precision and accuracy further encourages consumers to employ professional service robots. The revenue of personal service robotics segment is expected to grow at a rate of over 26% during the forecast period, owing to high demand of service robots from the domestic and entertainment sectors and rise in disposable income of consumers. In terms of volume, personal robots accounted for a higher share and generated over 4,672 thousand units in 2014. Healthcare is the major end user industry, in terms of revenue generation, that employs service robots for a wide range of applications such as surgery, diagnostics, physical and mental therapy, and prosthetics among others. Patient monitoring, laboratory automation, drug discovery, and prescription preparation are other applications of service robotics in the healthcare sector. It accounted for over 35% share of the global market revenue in 2014, followed by defense, rescue and security sector. Other industries utilizing service robotics include field, logistics, construction, domestic, and entertainment. The construction industry is likely to grow at the highest CAGR during the forecast period. In terms of volume, defense, rescue, & security robots accounted for the highest share and generated around 11 thousand units in 2014 owing to the increased employment of unmanned aerial vehicles, unmanned ground vehicles, firefighting & disaster management robots, professional surveillance robots, and demining robots. The healthcare segment is forecast to grow at the highest CAGR of 29.1% during 2015-2022 in terms of volume. Key findings of Service Robotics Market: 1. The service robotics market is projected to exhibit a significant growth owing to increasing demand of automation from various industries, rising application areas, and growth in emerging economies. 2. The professional robotics segment is anticipated to dominate the market in terms of revenue owing to the increasing applications from healthcare, defense, rescue and security, agriculture, logistics, and construction industries. 3. The healthcare industry is excepted to maintain its leading position in the market during the forecast period in terms of revenue. 4. Europe is likely to dominate the market throughout the forecast period. Prominent players offering service robotics solutions in the market include iRobot Corporation, Intuitive Surgical, Inc., Honda Motor Co., Ltd., Panasonic Corporation, and Aethon Inc. These players introduce new products to enhance their portfolios and collaborate with each other to strengthen and expand their market and geographical presence. Portland, OR, December 07, 2016 --( PR.com )-- The growing need of automation across various industries has encouraged organizations to adopt service robotics for increased productivity, superior quality and precise operations, reduced operation costs, and enhanced safety of workforce.Increasing need for safety along with government regulations for labor protection drives organizations to adopt service robotics for enhanced safety at workplace. The growing penetration of mobile devices facilitates the development of advanced robotic systems and boosts the growth of market. Vendors in the market focus on developing affordable and energy-efficient robots for small and medium enterprises to cater to the growing requirements of consumers. The significant rise in investments in R&D for the development of service robots along with the establishment of organizations including Standardized Procedures for the Advancement of Robotic Combat (SPARC) and International Federation of Robotics (IFR), further fosters the growth of the market.View more details of the report at: https://www.alliedmarketresearch.com/service-robotics-marketEurope dominated the global service robotics market in 2014 in terms of revenue and is expected to maintain its dominance during the forecast period owing to the high demand of service robots from domestic, healthcare, and defense sectors. However, LAMEA is expected to exhibit highest growth in revenue, at a CAGR of 26.6% during the forecast period.Professional service robots are used in healthcare; defense, rescue, and security; field; logistics; and construction industries. The segment of professional service robotics generated $3.9 billion in 2014 owing to high demand of automation from these sectors. Reduction in labor costs, increased operational efficiency, and delivery of high-quality services with improved precision and accuracy further encourages consumers to employ professional service robots. The revenue of personal service robotics segment is expected to grow at a rate of over 26% during the forecast period, owing to high demand of service robots from the domestic and entertainment sectors and rise in disposable income of consumers. In terms of volume, personal robots accounted for a higher share and generated over 4,672 thousand units in 2014.Healthcare is the major end user industry, in terms of revenue generation, that employs service robots for a wide range of applications such as surgery, diagnostics, physical and mental therapy, and prosthetics among others. Patient monitoring, laboratory automation, drug discovery, and prescription preparation are other applications of service robotics in the healthcare sector. It accounted for over 35% share of the global market revenue in 2014, followed by defense, rescue and security sector. Other industries utilizing service robotics include field, logistics, construction, domestic, and entertainment. The construction industry is likely to grow at the highest CAGR during the forecast period. In terms of volume, defense, rescue, & security robots accounted for the highest share and generated around 11 thousand units in 2014 owing to the increased employment of unmanned aerial vehicles, unmanned ground vehicles, firefighting & disaster management robots, professional surveillance robots, and demining robots. The healthcare segment is forecast to grow at the highest CAGR of 29.1% during 2015-2022 in terms of volume.Key findings of Service Robotics Market:1. The service robotics market is projected to exhibit a significant growth owing to increasing demand of automation from various industries, rising application areas, and growth in emerging economies.2. The professional robotics segment is anticipated to dominate the market in terms of revenue owing to the increasing applications from healthcare, defense, rescue and security, agriculture, logistics, and construction industries.3. The healthcare industry is excepted to maintain its leading position in the market during the forecast period in terms of revenue.4. Europe is likely to dominate the market throughout the forecast period.Prominent players offering service robotics solutions in the market include iRobot Corporation, Intuitive Surgical, Inc., Honda Motor Co., Ltd., Panasonic Corporation, and Aethon Inc. These players introduce new products to enhance their portfolios and collaborate with each other to strengthen and expand their market and geographical presence. Click here to view the list of recent Press Releases from Allied Market Research
News Article | December 8, 2016
The major growth driver of Virtualization Security Market includes growing demand for cloud computing and increasing demand for managed security services, and increasing demand for identity and access management among others. Hence the market for virtualization security is expected to grow at XX% CAGR (2016-2027). However, growing cyber-attacks and lack of technical expertise are the factors which are hindering the growth of Virtualization Security Market. • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the global virtualization security market. • To provide insights about factors affecting the market growth. • To analyze the virtualization reality market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW). • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segment by type, services, end-users, infrastructure and sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global virtualization security market . Global Virtualization Security Market can be segmented as follows: • Segmentation by Type: Hardware (Networking), Software (System & networking management, security management, operating system, virtual client computing software). • Segmentation by Services: Integration & design, consulting, and support & maintenance among others. • Segmentation by End-users: Cloud service provider, IT, telecommunication, healthcare & retail, government (BFSI), and large enterprises among others. • Segmentation by Infrastructure: Virtual switch, Hypervisor, web server, and virtual machine. North-America dominated the global virtualization security market with the largest market share due to high trend of server virtualization in US and also because of its one of the most frequent attack country in the region, and therefore accounting for $XX million and is expected to grow over $XX billion by 2027. Virtualization security market in European market is expected to grow at CAGR of XX% from $ XX million in 2016 to $XX million by 2027. The Asia-Pacific market for virtualization security market is expected to grow at XX% CAGR (2016-2027). Taste the market data and information presented through data tables and figures spread 100 pages of the project report. Avail in-depth table of content (TOC) & market synopsis on “Virtualization Security Market Research Report- Global Forecast to 2027” Some of the major players in Global Virtualization Security Market • Altor Networks (U.S.), • Trend Micro Inc. (Japan), • Symantec Corp. (U.S.), • VMware Inc. (U.S.), • Fortinet Inc. (U.S.), • Hewlett-Packard (U.S.), • Dell Inc. (U.S.), • Ericsson Networks (Sweden), • Intel Security Group (U.S.), • CA Technologies (U.S.) • Oracle Corporation among others. Industry News: • Cisco has announced in June 2016 about its new platform “Cisco tetration analytics” which is been designed to help customers to gain visibility over data centers in real time. The device collects telemetry information from hardware and software sensors and conduct analysis with the help of advanced machine learning techniques. • Oracle has announced in June 2016 about its new development SPARC which is designed to bring security, efficiency, and simplicity on cloud platform. About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. For more information, please visit https://www.marketresearchfuture.com/reports/virtualization-security-market-research-report-global-forecast-to-2027
News Article | September 21, 2016
What Advanced Innovative Engineering (AIE) lacks in creative company naming skill, it makes up for in its passion for advancing rotary engine technology. Its compact, lightweight 650S Wankel engine promises to alleviate problems with rotary design while offering the superior power-to-weight ratio rotaries are known for. The engine's small, lightweight size makes for easy integration within vehicles like the cherry red roadster AIE put to the track last week. Mazda may be the most famous automotive force behind the rotary engine, but it's not the only one out there with some interest in bringing the rotary roaring back. In June, we saw the LiquidPiston X engine and the Mini go-kart, and now we have a more adult-sized go-kart sporting a different breed of developmental rotary. AIE was established about four years ago with the objective of advancing rotary engine design. Its Wankel engine design began life as the patented work of David Garside, famous for his rotary experience at Norton Motorcycles, and AIE is further developing it for use in automotive, aerospace and marine applications. Specifically, it hopes to overcome the rotary's well-known drawbacks, like poor fuel economy and emissions performance, while capitalizing on power-to-weight advantages. The pillar of AIE's Wankel design is Garside's Self-Pressurizing-Air Rotor Air Cooling System (SPARCS), which uses gases from combustion to help in cooling. The company claims this technology prevents excessive oil losses by continuously recirculating oil, provides better thermal stability for improved efficiency in operation, and decreases strain on the seals and engine components. "The SPARCS cooling system for Wankel rotary engines utilizes the self-pressurizing blow by gases from the combustion process (which have escaped into the interior of the engine's core via the rotor's side seals) as a cooling medium," AIE explains of its design. "This pressurized air-gas mixture is recirculated in a completely closed loop circuit by an internal fan which is driven by the main shaft. As it recirculates, the air-gas mixture passes through the engine's rotor where it picks up heat before then being ducted through an external heat exchanger to reject the heat." AIE makes a number of SPARC-cooled rotary engines of different sizes, and the one used in its roadster is the 650S, a 650cc (40 cu in, 0.65 L) unit that puts out up to 120 bhp (89 kW) and 80 lb-ft (108 Nm). It measures 19.6 x 16.5 x 15 in (498 x 420 x 383 mm) and weighs 62 lb (28 kg), numbers AIE reckons make it 50 percent smaller and lighter than a comparable four-cylinder engine. For the past year, AIE has been working with automotive structural manufacturer Axon Automotive, whose tech was used in the Hyundai Intrado concept's carbon frame, and niche sports car maker Westfield Sportscars, whose work also includes the all-electric iRacer on a clean-driving, lightweight rotary roadster. The 650S rotary replaces the four-cylinder engine typically found in the Lotus 7-inspired Westfield roadster, held in place by an Axontex carbon fiber-based structure. "By partnering with Axon and Westfield, we want to demonstrate that it is possible to build a sports car that is both lightweight and great to drive," Axon managing director Nathan Bailey said of the project when it was announced last September. "By reducing the overall weight of the Westfield vehicle, this project will prove that a sports car doesn't need a heavy piston engine in order to deliver exciting performance." The 650S-powered Westfield is still a prototype, and after appearing at various 2016 shows, including the Goodwood Festival of Speed, it made its dynamic debut last week at the 2016 Cenex Low Carbon Vehicle Event. AIE has been generating interest in its rotary engines by touring around with the rotary roadster, and it plans to continue testing and improving the 650S's efficiency. In addition to working on rotary engines for directly powering cars and other vehicles, it is also exploring using its engines as range-extenders in electric vehicles. You can hear the rotary grumble and watch the car do its thing at the Millbrook Proving Ground in the clip below.
News Article | December 20, 2016
Charleston, South Carolina – The Charleston Digital Corridor, along with title sponsor Charleston County Economic Development, is pleased to announce the 2017 Innovators’ 5k (iFiveK) will be held at Riverfront Park in the City of North Charleston on April 13th, 2017 at 6:30pm. Proceeds from this annual race benefit the Digital Corridor’s CODEcamp scholarships and other education programming. Confirmed sponsors include Charleston tech companies BoomTown, Blackbaud, Benefitfocus and Google. “Charleston County Economic Development is honored to be the title sponsor for the 2017 iFiveK. We value our partnership with the Charleston Digital Corridor and our aligned efforts to foster growth in our local tech industry including support of hands-on learning opportunities like CODEcamp,” said Steve Dykes, Executive Director of Charleston County Economic Development. In addition to our returning sponsors, we are pleased to welcome the first of several new sponsors for 2017 – Atlatl Software and Snagajob. “Atlatl Software is proud to sponsor the iFiveK for the first time this year. We’re excited to support an event that brings our tech community together with the proceeds going directly to CODEcamp, an invaluable program that teaches adults and kids the fundamentals of web development while fostering innovation and a passion for technology in Charleston,” said Marc Murphy, CEO of Atlatl Software. The iFiveK has become a favorite athletic and networking event for Charleston’s tech community. As one of only a handful of evening weekday races in the region, the iFiveK historically sells out well ahead of the event. For 2017, the Charleston Digital Corridor has refreshed the iFiveK logo and branding and launched a new modernized, mobile-responsive website that enables race participants to register on the run. Registration for the iFiveK officially opens January 1, 2017. “It is awesome to see our tech community come together for a fun evening of competition and networking while supporting the further development of talent in Charleston,” said Digital Corridor Director, Ernest Andrade. “We're passionate about supporting Charleston's tech community, and the iFiveK gives us the opportunity to celebrate the hardworking, competitive and fun atmosphere that drives so many successful companies here, and put that culture to work for important initiatives," said Grier Allen, CEO & President of BoomTown. Additional committed sponsors for the 2017 iFiveK include eGroup, SPARC, CarePoint, Bibliolabs, Immedion, and local microbreweries Holy City Brewing and Cooper River Brewing Company. About: Innovators' 5K (iFiveK): The iFiveK is an annual event that brings together Charleston’s tech community for an evening of spirited competition and networking. Proceeds from the iFiveK support CODEcamp scholarships and other education programming. More: ifivek.com Charleston Digital Corridor: The Charleston Digital Corridor is a community-sourced initiative to attract, nurture and promote the regions tech economy through an array of impactful programs, products and events while leveraging Charleston’s renowned livability. More: charlestondigitalcorridor.com